Facing a steep price slide, Humana (HUM) valuation checks and Medicaid plans in South Carolina and Wisconsin have received a 2025 Press Ganey Human Experience Pinnacle of Excellence Award. An expanded partnership with Atlas is set to significantly improve cancer care, though there have been concerns about margin issues. Assessment reveals DCF and P/E suggest upside potential.
Several financial institutions are adjusting their holdings and opinions on HUM, while the company navigates mixed shareholder returns and potential undervaluation. Humana's Medicare Advantage plans show promise with 20% of members expected to be in higher-rated ones by 2026. Recently, they partnered with DrFirst to innovate in chronic condition patient care.
An executive change shows the Board's confidence in fresh strategies despite facing lowered earnings outlook due to high medical cost and mixed share price performance. Allspring Global Investments and other financial institutions have moved to augment their HUM holdings, pointing to a possible market reassessment. A newly won $7.3B Pentagon healthcare contract is another factor that could boost HUM's valuation.
Humana HUM News Analytics from Tue, 01 Jul 2025 07:00:00 GMT to Sat, 17 Jan 2026 14:47:42 GMT - Rating -1 - Innovation 2 - Information 4 - Rumor -1
